Co-Diagnostics Expected to Post Massive $3.60/Share Loss, Revenue Plunge
CODX is trading near its 52-week low of $1.66 (5.4% above the low) on light trading volume (0.3× avg).
Summary
Co-Diagnostics Inc is expected to report a substantial loss of $3.60 per share for the quarter ending December 31, 2025, according to analyst estimates. This projected loss is more than double the company's current stock price of $1.75, signaling severe financial underperformance. Analysts also anticipate a 15.4% decrease in quarterly revenue to a mere $126 thousand. This highly negative earnings preview, ahead of the March 31 report, suggests significant challenges for the company and could trigger substantial price movement. Traders will be closely watching the actual results for confirmation of these dire expectations.
At the time of this announcement, CODX was trading at $1.75 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $1.66 to $46.50. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.